Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824987 · ClinicalTrials.gov registry record · Phase 2
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
A Phase 2 study of APOL1-mediated Kidney Disease, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 20
- Study locations
NCT06824987 is a Phase 2 study of APOL1-mediated Kidney Disease that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 96 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT06824987, a Phase 2 study of APOL1-mediated Kidney Disease, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT AZD2373-Arm 1
- COMBINATION_PRODUCT AZD2373-Arm 2
- DEVICE APOL1 Genotyping Clinical Trial Assay
Study Locations (20)
Georgia
- Research Site - Atlanta
- Research Site - Augusta
- Research Site - Augusta
- Research Site - Columbus
- Research Site - Columbus
- Research Site - Duluth
- Research Site - Hinesville
- Research Site - Lawrenceville
Florida
- Research Site - Brandon
- Research Site - Miami
- Research Site - Miami
- Research Site - Orlando
- Research Site - Pompano Beach
California
- Research Site - Beverly Hills
- Research Site - Gardena
- Research Site - Los Angeles
- Research Site - Valencia
Alabama
- Research Site - Alabaster
- Research Site - Birmingham
- Research Site - Irondale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2027-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06824987
The ClinicalTrials.gov registry entry for NCT06824987 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with APOL1-mediated Kidney Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06824987 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Georgia, Florida, California.
Frequently Asked Questions
What is clinical trial NCT06824987 about?
NCT06824987 is a clinical study titled "Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease". The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with...
What is the current status of trial NCT06824987?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2025-03-05. Estimated completion is 2027-08-30.
What conditions does trial NCT06824987 study?
This clinical trial studies the following conditions: APOL1-mediated Kidney Disease.
What interventions are being tested in trial NCT06824987?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), AZD2373-Arm 1 (COMBINATION_PRODUCT), AZD2373-Arm 2 (COMBINATION_PRODUCT), APOL1 Genotyping Clinical Trial Assay (DEVICE).
Who is sponsoring clinical trial NCT06824987?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06824987 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for APOL1-mediated Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.